Affordable Access

23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial.

Authors
  • French, N
  • Nakiyingi, J
  • Carpenter, L M
  • Lugada, E
  • Watera, C
  • Moi, K
  • Moore, M
  • Antvelink, D
  • Mulder, D
  • Janoff, E N
  • Whitworth, J
  • Gilks, C F
Type
Published Article
Journal
The Lancet
Publisher
Elsevier BV
Publication Date
Jun 17, 2000
Volume
355
Issue
9221
Pages
2106–2111
Identifiers
PMID: 10902624
Source
Medline
Keywords
License
Unknown

Abstract

23-valent pneumococcal polysaccharide vaccination is ineffective in HIV-1-infected Ugandan adults and probably has little, or no, public health value elsewhere in sub-Saharan Africa. Increased rates of pneumococcal disease in vaccine recipients may necessitate a reappraisal of this intervention in other settings.

Report this publication

Statistics

Seen <100 times